Search Results
Jul 30, 2026, 12:33 ET Piramal Pharma Limited annuncia i risultati del primo trimestre dell'anno fiscale 2027
margine EBITDA nella maggior parte delle sedi, nonostante le pressioni inflazionistiche.Rafforzamento delle nostre capacità ADC: abbiamo inaugurato la suite di linker per carichi utili su scala commerciale a Riverview (USA), mentre l'espansione della capacità di produzione
More news about: Piramal Pharma Limited
Jul 30, 2026, 10:31 ET Piramal Pharma Limited annonce ses résultats pour le T1 2027
d'accroître la marge du BAIIA sur la plupart des sites, malgré les pressions inflationnistes.Renforcement de nos capacités ADC : mise en service de l'unité de charge utile-linker à échelle commerciale de Riverview (États-Unis), tandis que l'extension des capacités de produits
More news about: Piramal Pharma Limited
Jul 30, 2026, 10:02 ET Capsa Healthcare Introduces the Pharmacy Engine: RoboPharma, Powered by Axona
clinic distribution: clinic inventory management, clinical cart fill, batch preparation and delivery to every care settingCabinet and ADC replenishment: order generation, par management and stockout prevention at the point of careThe list grows by design. When orchestration,
More news about: Capsa Healthcare
Jul 30, 2026, 06:39 ET Piramal Pharma Limited gibt die Ergebnisse für das erste Quartal des Geschäftsjahres 2027 bekannt
Exzellenz führten trotz Inflationsdruck zu einer Steigerung der EBITDA-Marge an den meisten Standorten.Ausbau unserer ADC-Kompetenzen: In Riverview (USA) wurde die Anlage zur Herstellung von Payload-Linkern im kommerziellen Maßstab in Betrieb genommen, während die Kapazitätserweiterung
More news about: Piramal Pharma Limited
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jul 30, 2026, 04:27 ET Piramal Pharma Limited anuncia sus resultados para el primer trimestre del año fiscal 2027
margen EBITDA en la mayoría de las plantas, a pesar de las presiones inflacionistas.Desarrollo de nuestras capacidades en ADC: Se inauguró la línea de producción a escala comercial de enlaces de carga útil en Riverview (Estados Unidos), mientras que la ampliación de la capacidad
More news about: Piramal Pharma Limited
Jul 29, 2026, 15:38 ET Piramal Pharma Limited Announces Results for Q1 FY27
operational excellence drove EBITDA margin expansion across most sites despite inflationary pressures.Building upon our ADC Capabilities: Inaugurated the commercial-scale payload-linker suite at Riverview (US), while the Lexington (US) sterile injectable capacity expansion
More news about: Piramal Pharma Limited
Jul 29, 2026, 15:27 ET Piramal Pharma Limited Announces Results for Q1 FY27
operational excellence drove EBITDA margin expansion across most sites despite inflationary pressures.Building upon our ADC Capabilities: Inaugurated the commercial-scale payload-linker suite at Riverview (US), while the Lexington (US) sterile injectable capacity expansion
More news about: Piramal Pharma Limited
Jul 27, 2026, 22:35 ET Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
developed next-generation differentiated HER3 ADC, AK138D1, as monotherapy or in combination with ivonescimab (PD-1/VEGF bispecific antibody) for advanced non-small cell lung cancer (NSCLC). The study aims to evaluate the potential of Akeso's IO2.0 + ADC2.0 regimen across multiple settings in advanced
More news about: Akeso, Inc.
Jul 27, 2026, 09:00 ET AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem
delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for
More news about: AsymBio
Jul 27, 2026, 07:30 ET Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
proprietary ADC portfolio; on the other hand, the Company is advancing integrated drug design strategies by incorporating synergistic functional components into a single ADC molecule.Dr. Michael Ge, CEO of Kelun-Biotech, said, " SKB565 is one of the core representative drugs of our integrated 'ADC + IO'
More news about: Kelun-Biotech
Jul 27, 2026, 07:24 ET 首個雙載荷ADC進入臨床，科倫博泰SKB565獲臨床試驗批准通知書
全性，其突出的腫瘤治療潛力為後續臨床開發提供了有力支撐。憑藉在ADC領域的技術沉澱與平臺優勢，科倫博泰已佈局一系列結合高價值靶點、差異化設計並具備全球潛力的創新分子。在此基礎上，公司進一步拓展「ADC+IO」策略——一方面聚焦優質聯用療法的探索，包括正在開展臨床的多種ADC與PD-(L)1單抗聯合方案，以及PD-1/VEGF雙抗SKB118與公司眾多專有ADC資產的聯用；另一方面推進一體化策略研發，在單一ADC分子中整合具有協同作用機制功能元件。科倫博泰首席執行官葛均友博士表示：「SKB565是我們『A
More news about: 科倫博泰
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
key ALCL companies, including Takeda Pharmaceutical Company, Bristol Myers Squibb, Merck & Co., F. Hoffmann-La Roche, Novartis, Pfizer, Genmab, ADC Therapeutics, Citius Pharmaceuticals, Affimed, and others.About DelveInsightDelveInsight is a leading Business Consultant
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 08:47 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25. The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety
More news about: Bio-Thera Solutions, Ltd
Jul 20, 2026, 23:50 ET ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid,
More news about: Mabwell
Jul 20, 2026, 07:30 ET Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
therapies to treat a broad range of rare and common diseases, today announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, to be held October
More news about: Biohaven Ltd.
Jul 20, 2026, 03:00 ET Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jul 20, 2026, 01:32 ET Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
combination, with a particular emphasis on the first-line treatment setting. The advancement of ADC 2.0 candidates AK146D1 and AK138D1 into Phase II trials marks a critical milestone for Akeso's "IO2.0 + ADC2.0" strategy. Built upon our proprietary bispecific and multispecific antibody technology alongside
More news about: Akeso, Inc.
Jul 17, 2026, 09:00 ET IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
treatment option across the uveal melanoma patient journey. We also hope to highlight the potential best-in-class profile of IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs, where monotherapy and combination trials are ongoing and the program's first registrational trial is targeted to initiate by year-end
More news about: IDEAYA Biosciences, Inc.
Jul 17, 2026, 08:00 ET SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
recurrent or metastatic nasopharyngeal carcinoma (NPC), further establishing iza-bren as a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) with broad clinical potential across multiple solid tumors.The approval is supported by results from the pivotal PANKU-Esophagus01 (BL-B01D1-305)
More news about: SystImmune, Inc.
Jul 15, 2026, 08:45 ET CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development
China.Nucleai is a tissue intelligence company applying AI-based image and clinical analysis to biopharma drug development, with a track record across ADC clinical programs and CTA development and deployment under QMS.Tivenix expands the Consortium's precision diagnostics reach through AI-enabled
More news about: CellCarta
Jul 15, 2026, 06:01 ET Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Harbour BioMed
Jul 15, 2026, 06:00 ET Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jul 14, 2026, 20:00 ET 全球首個ADC+IO對比免疫聯合化療一線治療PD-L1陰性非鱗狀NSCLC III期研究達到主要終點，蘆康沙妥珠單抗聯合帕博利珠單抗有望重塑治療格局
NSCLC患者，免疫聯合化療作為一線標準治療雖在一定程度上改善了患者預後，但其長期生存獲益仍然有限。此次OptiTROP-Lung06 III期已達到主要終點，是PD-L1陰性NSCLC一線治療領域的一項重要突破，該研究不僅為蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗這一『ADC+IO』方案提供了堅實的循證醫學證據，更有望為這類患者帶來超越當前標準治療的全新一線選擇，實現更優的生存獲益。」科倫博泰首席執行官葛均友博士表示：「很高興看到蘆康沙妥珠單抗(sac-TM
More news about: 科倫博泰
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech